Summary
SLC13A5 citrate transporter disorder is a rare genetic condition that affects multiple parts of the body, most notably the brain. It is caused by changes in the SLC13A5 gene, which helps move citrate (a type of chemical) into cells. Children living with this disorder often have seizures starting in the first days of life. Other symptoms include delays in learning, movement, and speech, as well as dental problems. The disorder is lifelong.
Description
SLC13A5 citrate transporter disorder happens when the body cannot use citrate properly. When the SLC13A5 gene does not work, the brain cannot develop as it should, leading to seizures and developmental delays. Patients affected by SLC13A5 citrate transporter disorder experience a range of symptoms, from mild to severe. A majority of affected individuals experience more severe symptoms that begin shortly after birth. Some children may eventually walk, understand what is being told to them, and speak a few words. A majority of affected individuals need help with daily life including:
- Dressing
- Toileting
- Bathing
- Communicating
- Eating
- Sleeping
Affected individuals will need lifelong support. With the appropriate medications, many affected children have reduced seizures as they get older.
SLC13A5 citrate transporter disorder is known by many different names:
- SLC13A5 Epilepsy
- SLC13A5 Deficiency
- Early infantile epileptic encephalopathy 25 (EIEE25)
- Developmental and epileptic encephalopathy 25 (DEE25)
- Kohlschütter-Tönz syndrome (non-ROGDI)
Signs and Symptoms
To diagnose SLC13A5 citrate transporter disorder, doctors look for:
- Seizures starting in the first days of life
- Delays in walking, talking, and learning
- Movement problems, such as shaky or stiff muscles
- Teeth that are widely spaced, come in late, or have weak enamel
- Genetic testing that shows a change to the SLC13A5 gene
Additional symptoms that are often missed or delayed include:
- Trouble feeding
- Weak muscles
- Trouble swallowing
- Lack of muscle control and/or coordination of voluntary movements
- Learning and speech delays that become more apparent as the child gets older
Causes
No one causes this disorder by anything they do. People who become pregnant experience a typical pregnancy and do not cause SLC13A5 citrate transporter disorder by anything they do during pregnancy. SLC13A5 citrate transporter disorder is inherited from both parents, who each carry one changed SLC13A5 gene and one healthy SLC13A5 gene. Biological parents each give one copy of the SLC13A5 gene to their child. If a child receives two changed SLC13A5 genes, the body cannot use citrate properly and this causes SLC13A5 citrate transporter disorder. Parents often do not know that they have a changed SLC13A5 gene because a person only needs one healthy SLC13A5 gene to use citrate properly.
Laboratory Investigations
Diagnosis may include:
- Genetic testing (blood test) to look for changes in the SLC13A5 gene
- Brain scans, such as MRI, to check for other problems
- EEG (electroencephalogram) to look at brain activity and seizures
- Blood or urine tests to check for high citrate levels
Most tests are done once, but EEG or brain scans may be repeated if needed.
Treatment and Therapies
There is no cure, but treatments can help manage symptoms.
Treatment options include:
- Medicines to help control seizures (often more than one is needed)
- Physical therapy to improve movement or ability
- Aquatic therapy: physical therapy in the water
- Hippotherapy: using the natural gait of a horse to provide motor and sensory input
- Occupational Therapy to support everyday activities
- Feeding support: some people may need feeding tubes
- Speech therapist to support communication
- Dental care for tooth problems
- Use of assistive communication devices
Children affected by SLC13A5 citrate transporter disorder may also benefit from the following:
- Seizure action plan
- Durable medical equipment
- Adaptive strollers
- Wheelchairs
- Walkers
- Standers
- Child life specialist
- Social worker
- Individualized Education Program (IEP)
Outlook
With treatment, children may learn and develop some skills. This disorder does not go away with age but symptoms may change as children grow. Most affected individuals will need round-the-clock care throughout life. To date, a majority of individuals require care into and throughout adulthood. Daily life, school, and family routines are affected. Children may need special help at school and at home. Diet and exercise do not cure the disorder, but a healthy lifestyle is still important. This includes support for family members. Families may need to adjust routines and daily activities to support their child.
Resources
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
TESS Research Foundation drives cutting-edge research to diagnose, treat, and ultimately cure SLC13A5 Epilepsy, while providing support for affected children and their families.
Research
ClinicalTrials.gov for SLC13A5 (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
Family Stories
The TESS Research Foundation shares inspiring family stories and the journeys of some of their “SLC13A5 Superheroes” along with other news and updates for the community.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
Bainbridge MN, Cooney E, Miller M, et al. Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle. Mol Genet Metab. 2017;121(4):314-319. doi:10.1016/j.ymgme.2017.06.009
Brown TL, Bainbridge MN, Zahn G, Nye KL, Porter BE. The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization. Ther Adv Rare Dis. 2024;5:26330040241263972. doi:10.1177/26330040241263972
Hardies K, de Kovel CGF, Weckhuysen S, et al. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Brain. 2015;138(Pt 11):3238-3250. doi:10.1093/brain/awv263
Matricardi S, De Liso P, Freri E, et al. Neonatal developmental and epileptic encephalopathy due to autosomal recessive variants in SLC13A5 gene. Epilepsia. 2020;61(11):2474-2485. doi:10.1111/epi.16699
Spelbrink EM, Brown TL, Brimble E, Blanco KA, Nye KL, Porter BE. Characterizing a rare neurogenetic disease, SLC13A5 citrate transporter disorder, utilizing clinical data in a cloud-based medical record collection system. Front Genet. 2023;14:1109547. doi:10.3389/fgene.2023.1109547
Thevenon J, Milh M, Feillet F, et al. Mutations in SLC13A5 Cause Autosomal-Recessive Epileptic Encephalopathy with Seizure Onset in the First Days of Life. The American Journal of Human Genetics. 2014;95(1):113-120. doi:10.1016/j.ajhg.2014.06.006
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory